Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $21.67, but opened at $20.77. Dianthus Therapeutics shares last traded at $21.59, with a volume of 14,201 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DNTH shares. Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $54.33.

Dianthus Therapeutics Price Performance

The stock has a market cap of $677.38 million, a price-to-earnings ratio of -8.43 and a beta of 1.62. The business has a fifty day moving average of $19.97 and a 200 day moving average of $22.84.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $26,000. KLP Kapitalforvaltning AS bought a new position in Dianthus Therapeutics in the 4th quarter worth $33,000. KBC Group NV acquired a new position in Dianthus Therapeutics during the 4th quarter worth $35,000. BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at about $59,000. Finally, GAMMA Investing LLC increased its stake in shares of Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock worth $70,000 after purchasing an additional 3,758 shares during the period. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.